Publicaciones en colaboración con investigadores/as de Beth Israel Deaconess Medical Center (5)

2021

  1. Motixafortide and pembrolizumab combined to nanoliposomal irinotecan, fluorouracil, and folinic acid in metastatic pancreatic cancer: The COMBAT/ KEYNOTE-202 trial

    Clinical Cancer Research, Vol. 27, Núm. 18, pp. 5020-5027

2020

  1. BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial

    Nature Medicine, Vol. 26, Núm. 6, pp. 878-885

2017

  1. Results from an integrated safety analysis of urelumab, an agonist anti-CD137 monoclonal antibody

    Clinical Cancer Research, Vol. 23, Núm. 8, pp. 1929-1936

2011

  1. Defining the critical hurdles in cancer immunotherapy

    Journal of Translational Medicine

2009

  1. Chromatin signature reveals over a thousand highly conserved large non-coding RNAs in mammals

    Nature, Vol. 458, Núm. 7235, pp. 223-227